Literature DB >> 10450805

Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C.

H Harada1, A Tamaoka, Y Kohno, A Mochizuki, S Shoji.   

Abstract

We report the case of a 53-year-old female patient, who developed bilateral blepharoptosis, limb weakness, dysphagia, and dyspnea several days after human natural interferon-beta (IFN-beta) treatment for chronic active hepatitis C. A positive edrophonium test, an elevated anti-acetylcholine receptor antibody titer, and decrements in the amplitude of muscle action potentials evoked by repetitive stimulation confirmed the diagnosis of myasthenia gravis (MG). Since she had been suffering from drooping of her right eyelid, fluctuating diplopia and easy fatiguability of limbs before receiving IFN-beta, her symptoms of MG were considered to be exacerbated by IFN-beta. It is recommended that IFN-beta should be used with particular care in patients with known MG or its compatible symptoms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450805     DOI: 10.1016/s0022-510x(99)00082-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy.

Authors:  A Oishi; K Miyamoto; S Kashii; N Yoshimura
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.

Authors:  Kimitoshi Kimura; Yoichiro Okada; Chihiro Fujii; Kenichi Komatsu; Ryosuke Takahashi; Sadayuki Matsumoto; Takayuki Kondo
Journal:  J Neurol       Date:  2019-07-24       Impact factor: 4.849

3.  Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report.

Authors:  Su Jung Baik; Tae Hun Kim; Hye In Kim; Jeong Yeon Rhie
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.